ONCT — Oncternal Therapeutics Share Price
0.000.00%
Last trade - 00:00- $1.56m
- -$13.02m
- $0.79m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.17 | ||
| Price to Tang. Book | 0.17 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.72 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -393.08% | ||
| Return on Equity | -149.86% | ||
| Operating Margin | -1664% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2.42 | 3.38 | 4.32 | 1.49 | 0.79 | 1.92 | 0.6 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.
Directors
- David Hale NEC (72)
- James Breitmeyer PRE (67)
- Richard Vincent CFO (58)
- Gunnar Kaufmann CSO (45)
- Chase Leavitt GCN (39)
- Salim Yazji OTH
- Robert Wills DRC (67)
- Nakanishi Xin DRC (59)
- Michael Carter IND (83)
- Daniel Kisner IND (74)
- William LaRue IND (70)
- Rosemary Mazanet IND (65)
- Charles Theuer IND (57)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- September 4th, 2003
- Public Since
- February 3rd, 2004
- No. of Shareholders
- 88
- No. of Employees
- 27
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 2,959,645
- Address
- 12230 EL CAMINO REAL, SUITE 230, SAN DIEGO, 92130
- Web
- https://www.oncternal.com/
- Phone
- +1 8584341113
- Auditors
- BDO USA, P.C.
Upcoming Events for ONCT
Q1 2025 Oncternal Therapeutics Inc Earnings Release
Similar to ONCT
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Achilles Therapeutics
NASDAQ Capital Market
FAQ
What is the Oncternal Therapeutics share price?
As of Today at 21:26 UTC, shares in Oncternal Therapeutics are trading at $0.53. This share price information is delayed by 15 minutes.
How has the Oncternal Therapeutics share price performed this year?
Shares in Oncternal Therapeutics last closed at $0.53 and the price had moved by -92.3% over the past 365 days. In terms of relative price strength the Oncternal Therapeutics share price has underperformed the S&P500 Index by -94.18% over the past year.
What are the analyst and broker recommendations for Oncternal Therapeutics?
The overall consensus recommendation for Oncternal Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Oncternal Therapeutics dividend yield?
Oncternal Therapeutics does not currently pay a dividend.
Does Oncternal Therapeutics pay a dividend?
Oncternal Therapeutics does not currently pay a dividend.
When does Oncternal Therapeutics next pay dividends?
Oncternal Therapeutics does not currently pay a dividend.
How do I buy Oncternal Therapeutics shares?
To buy shares in Oncternal Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Oncternal Therapeutics?
As of the previous close price of $0.53, shares in Oncternal Therapeutics had a market capitalisation of $1.56m.
Where are Oncternal Therapeutics shares listed?
Here are the trading details for Oncternal Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ONCT
What kind of share is Oncternal Therapeutics?
Based on an overall assessment of its quality, value and momentum Oncternal Therapeutics is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Oncternal Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Oncternal Therapeutics is $2.00. That is 279.79% above the last closing price of $0.53.
Analysts covering Oncternal Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$12.43 for the next financial year.
Find out moreWhat is the trend in the Oncternal Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oncternal Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -94.73%.
As of the last closing price of $0.53, shares in Oncternal Therapeutics were trading -90.96% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Oncternal Therapeutics PE Ratio?
The Oncternal Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.53.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Oncternal Therapeutics?
Oncternal Therapeutics' management team is headed by:
- David Hale - NEC
- James Breitmeyer - PRE
- Richard Vincent - CFO
- Gunnar Kaufmann - CSO
- Chase Leavitt - GCN
- Salim Yazji - OTH
- Robert Wills - DRC
- Nakanishi Xin - DRC
- Michael Carter - IND
- Daniel Kisner - IND
- William LaRue - IND
- Rosemary Mazanet - IND
- Charles Theuer - IND